IGF-1R Down Regulates the Sensitivity of Hepatocellular Carcinoma to Sorafenib Through the PI3K / Akt and RAS / Raf / ERK Signaling Pathways

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2023 Jan 26

PMID 36698167

Authors

Wenpeng Cai

Yongfang Ma

Li Song

Niandie Cao

Jiafeng Gao

Shuping Zhou

Xiaolong Tang

Affiliations

Soon will be listed here.

Abstract

Background: Insulin-like growth factor-1 receptor (IGF-1R) promotes cell proliferation and migration and inhibitsapoptosis, all of which can contribute to the development of cancers.

Method: This study investigated the effect and mechanism of IGF-1R in mediating the desensitization of hepatocellular carcinoma (HCC) to sorafenib.

Results: IGF-1R, highly expressed in the HCC cell lines SK-Hep1 and HepG2, promotes cell proliferation, migration, and anti-apoptosis through PI3K / Akt and RAS / Raf / ERK signaling pathways, resulting in HCC resistance to sorafenib. Knockdown of IGF-1R by RNA interference decreased proliferation and cell migration and upregulation of sorafenib-induced apoptosis of HCC cells. In vivo studies demonstrated that IGF-1R knockdown inhibited the growth of SK-Hep1 xenografts.

Conclusion: These data are evidence that IGF-1R participates in regulating the survival and cell growth of HCC through the PI3K / Akt and RAS / Raf / ERK signaling pathways. Intervention in the expression of IGF-1R may increase the inhibitory effect of sorafenib on HCC.

Citing Articles

Roles of clinical application of lenvatinib and its resistance mechanism in advanced hepatocellular carcinoma (Review).

Ye G, Ye M, Jin X Am J Cancer Res. 2024; 14(9):4113-4171.

PMID: 39417171 PMC: 11477829. DOI: 10.62347/UJVP4361.

Effects of T2DM on cancer progression: pivotal precipitating factors and underlying mechanisms.

Zhang Y, Li Y, Xue C, Li S, Gao Z, Qin K Front Endocrinol (Lausanne). 2024; 15:1396022.

PMID: 39290325 PMC: 11405243. DOI: 10.3389/fendo.2024.1396022.

Signaling pathways in liver cancer: pathogenesis and targeted therapy.

Xue Y, Ruan Y, Wang Y, Xiao P, Xu J Mol Biomed. 2024; 5(1):20.

PMID: 38816668 PMC: 11139849. DOI: 10.1186/s43556-024-00184-0.

CBX1 is involved in hepatocellular carcinoma progression and resistance to sorafenib and lenvatinib via IGF-1R/AKT/SNAIL signaling pathway.

Zheng S, Wu J, Wu W, Hu J, Zhang D, Huang C Hepatol Int. 2024; 18(5):1499-1515.

PMID: 38769286 PMC: 11461582. DOI: 10.1007/s12072-024-10696-0.

Molecular Genealogy of Metabolic-associated Hepatocellular Carcinoma.

Kodama T, Takehara T Semin Liver Dis. 2024; 44(2):147-158.

PMID: 38499207 PMC: 11245329. DOI: 10.1055/a-2289-2298.

References

Aaltonen K, Rosendahl A, Olsson H, Malmstrom P, Hartman L, Ferno M . Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer. BMC Cancer. 2014; 14:794. PMC: 4232733. DOI: 10.1186/1471-2407-14-794. View

Werner H, Sarfstein R, Laron Z . The Role of Nuclear Insulin and IGF1 Receptors in Metabolism and Cancer. Biomolecules. 2021; 11(4). PMC: 8065599. DOI: 10.3390/biom11040531. View

Forbes B, Blyth A, Wit J . Disorders of IGFs and IGF-1R signaling pathways. Mol Cell Endocrinol. 2020; 518:111035. DOI: 10.1016/j.mce.2020.111035. View

Ma Y, Xu R, Liu X, Zhang Y, Song L, Cai S . LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells. Int J Med Sci. 2021; 18(6):1456-1464. PMC: 7893555. DOI: 10.7150/ijms.51256. View

Xu R, Zhang Y, Li A, Ma Y, Cai W, Song L . LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway. Mol Med Rep. 2021; 24(1). PMC: 8134878. DOI: 10.3892/mmr.2021.12147. View

Chen H, Sharon E . IGF-1R as an anti-cancer target--trials and tribulations. Chin J Cancer. 2013; 32(5):242-52. PMC: 3845553. DOI: 10.5732/cjc.012.10263. View

Kim D, Talati C, Kim R . Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy. J Gastrointest Oncol. 2017; 8(2):256-265. PMC: 5401857. DOI: 10.21037/jgo.2016.09.07. View

Zhou S, Ma Y, Xu R, Tang X . Nanoparticles Loaded with GSK1059615 Combined with Sorafenib Inhibited Programmed Cell Death 1 Ligand 1 Expression by Negatively Regulating the PI3K/Akt/NF-B Pathway, Thereby Reversing the Drug Resistance of Hepatocellular Carcinoma to Sorafenib. J Biomed Nanotechnol. 2022; 18(3):693-704. DOI: 10.1166/jbn.2022.3279. View

Farabaugh S, Litzenburger B, Elangovan A, Pecar G, Walheim L, Atkinson J . IGF1R constitutive activation expands luminal progenitors and influences lineage differentiation during breast tumorigenesis. Dev Biol. 2020; 463(1):77-87. PMC: 7297516. DOI: 10.1016/j.ydbio.2020.04.007. View

10.

Bie C, Liu X, Cao M, Huang Q, Tang H, Wang M . Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits the growth and invasion of hepatocellular carcinoma via down-regulating midkine expression. Oncotarget. 2016; 7(48):79305-79318. PMC: 5346715. DOI: 10.18632/oncotarget.13027. View

11.

Zhang Y, Liu X, Li A, Tang X . A pan-cancer analysis on the carcinogenic effect of human adenomatous polyposis coli. PLoS One. 2022; 17(3):e0265655. PMC: 8932560. DOI: 10.1371/journal.pone.0265655. View

12.

Xu J, Ji L, Ruan Y, Wan Z, Lin Z, Xia S . UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma. Signal Transduct Target Ther. 2021; 6(1):190. PMC: 8129126. DOI: 10.1038/s41392-021-00594-4. View

13.

Wang Y, Wang Z, Qiu Y, Xiong J, Chen Y, Miao D . Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits growth, reduces invasion, and enhances radiosensitivity in human osteosarcoma cells. Mol Cell Biochem. 2009; 327(1-2):257-66. DOI: 10.1007/s11010-009-0064-y. View

14.

Huang A, Yang X, Chung W, Dennison A, Zhou J . Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020; 5(1):146. PMC: 7419547. DOI: 10.1038/s41392-020-00264-x. View

15.

Zorea J, Prasad M, Cohen L, Li N, Schefzik R, Ghosh S . IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer. Cell Death Dis. 2018; 9(10):944. PMC: 6148236. DOI: 10.1038/s41419-018-1025-8. View

16.

Bruchim I, Attias Z, Werner H . Targeting the IGF1 axis in cancer proliferation. Expert Opin Ther Targets. 2009; 13(10):1179-92. DOI: 10.1517/14728220903201702. View

17.

Zhang Y, Cao N, Gao J, Liang J, Liang Y, Xie Y . ASIC1a stimulates the resistance of human hepatocellular carcinoma by promoting EMT via the AKT/GSK3β/Snail pathway driven by TGFβ/Smad signals. J Cell Mol Med. 2022; 26(10):2777-2792. PMC: 9097844. DOI: 10.1111/jcmm.17288. View

18.

Shali H, Ahmadi M, Kafil H, Dorosti A, Yousefi M . IGF1R and c-met as therapeutic targets for colorectal cancer. Biomed Pharmacother. 2016; 82:528-36. DOI: 10.1016/j.biopha.2016.05.034. View

19.

Janssen J . New Insights from IGF-IR Stimulating Activity Analyses: Pathological Considerations. Cells. 2020; 9(4). PMC: 7226833. DOI: 10.3390/cells9040862. View

20.

Ghafouri-Fard S, Abak A, Mohaqiq M, Shoorei H, Taheri M . The Interplay Between Non-coding RNAs and Insulin-Like Growth Factor Signaling in the Pathogenesis of Neoplasia. Front Cell Dev Biol. 2021; 9:634512. PMC: 7985092. DOI: 10.3389/fcell.2021.634512. View